Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19
Year: 2023
Type: erratum
Abstract: The original version of this article contained an error in the Abstract, which incorrectly omitted from the end the following: ‘Trial Registration: ClinicalTrials.gov Identifier: NCT04518410’. This has been corrected in both the PDF and HTML versions of the Article.
Source: Nature Communications
Authors: Kara W. Chew, Carlee Moser, Eric S. Daar, David A. Wohl, Jonathan Z. Li, Robert W. Coombs, Justin Ritz, Mark Giganti, Arzhang Cyrus Javan, Yijia Li, Manish C. Choudhary, Rinki Deo, Carlos Malvestutto, Paul Klekotka, Karen Price, Ajay Nirula, William Fischer, Veenu Bala, Ruy M. Ribeiro, Alan S. Perelson, Courtney V. Fletcher, Joseph J. Eron, Judith S. Currier, ACTIV-2/A5401 Study Team, Michael D. Hughes, Davey M. Smith
Institutions: University of California, Los Angeles, Harvard University, The Lundquist Institute, Harbor–UCLA Medical Center, University of North Carolina at Chapel Hill, Brigham and Women's Hospital, University of Washington, National Institutes of Health, University of Pittsburgh, The Ohio State University Wexner Medical Center, Eli Lilly (United States), Jounce Therapeutics (United States), University of Nebraska Medical Center, Los Alamos National Laboratory, University of California San Diego
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $6,290
Awards: G1050281965, G961682679
OpenAlex ID: W4317501583